Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
O-specific polysaccharide of Shigella flexneri serotype 2a
- Molecular classification
- Other (Bacterial surface polysaccharide), Other (Vaccine antigen)
01
Overview
The O-specific polysaccharide of Shigella flexneri serotype 2a is a repeating tetrasaccharide component of the bacterium’s outer membrane lipopolysaccharide (LPS), serving as the defining antigenic determinant for serotyping, crucial for virulence, and the main immunogen in vaccine development. Its basic structure contains three L-rhamnose residues and one N-acetylglucosamine (GlcNAc), with serotype-specific modifications such as 4-position glucosylation (conferred by gtrII) and O-acetylations (mediated by oacB and oacD), which influence both immune recognition and bacterial resistance to host defenses. As the primary antigenic target, it evokes a protective immune response via specific antibodies, making it central to subunit and conjugate vaccine strategies against shigellosis.
- Other names
- O-antigen polysaccharide of Shigella flexneri 2aS. flexneri 2a O-specific polysaccharideSf2a O-PSO-antigen of Shigella flexneri 2a
02
Mechanism of action
Elicitation of protective antibodies (block bacterial invasion, promote opsonization) Acts as the immunogen for vaccine-induced immune response
03
Biological functions
Immune response (antigenic determinant stimulating protective host immunity)Bacterial outer membrane stabilityFacilitates pathogenesis (enables invasion and immune evasion)
04
Disease associations
Infection (shigellosis)Other (vaccine and serotyping target)
05
Safety considerations
Antigen variability may reduce vaccine efficacyStructural modifications (O-acetylation, glucosylation) can alter immune recognition and serotype coverage
06
Interacting drugs
No direct small molecule drugs; interacts with vaccine candidates (e.g., conjugate vaccines, synthetic O-antigen mimetics)
1 more in the full profile.
07
Biomarkers
Presence of anti-O-antigen IgG (such as F22-4) as a marker for vaccine response or infection
Beyond the preview
Go deeper on O-specific polysaccharide of Shigella flexneri serotype 2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on O-specific polysaccharide of Shigella flexneri serotype 2a.